ITCI - イントラセルラ―・セラピ―ズ (Intra-Cellular Therapies Inc.) イントラセルラ―・セラピ―ズ

 ITCIのチャート


 ITCIの企業情報

symbol ITCI
会社名 Intra-Cellular Therapies Inc (イントラセルラ―・セラピ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イントラ・セルラー・セラピーズ(Intra-Cellular Therapies Inc.)はバイオ医薬品会社である。同社は中枢神経系(CNS)内の細胞内シグナル伝達機構を標的とすることにより、神経精神医学的および神経学的障害における不十分な医学的ニーズに対処する小分子薬物の発見・臨床開発を行う。同社は神経学的および精神医学的障害の治療のための薬物を発見・開発する。ルマテペロン(ITI-007)は、主要製品候補である。同社の双極性うつ病プログラムは、2つの第III相多施設、無作為化、二重盲検、プラセボ対照臨床試験で構成される。1つは単独治療としてルテテペロンを評価し、もう1つはリチウムまたはバルプロエートによる補助療法としてルテテペロンを評価する。同社は、アルツハイマー病(AD)を含む認知症患者の激越の治療のためのルテテペロンの第III相開発を開始した。   イントラセルラ―・セラピ―ズは、米国のバイオ製薬企業。中枢神経系内の細胞内シグナル伝達機構を標的とする神経精神障害および神経障害に対処する小分子薬の発見と臨床開発に焦点を当てる。主要製品候補は、統合失調症のためのファ―ストインクラスの治療薬「ITI-007」、統合失調症および認知障害の治療薬「 ITI-002」がある。   Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.
本社所在地 430 East 29th Street New York NY 10016 USA
代表者氏名 Lawrence J. Hineline ローレンスJ.ヒネリン
代表者役職名 Chief Financial Officer Vice President - Finance Treasurer Assistant Secretary
電話番号 +1 212-923-3344
設立年月日 41122
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 49人
url www.intracellulartherapies.com
nasdaq_url https://www.nasdaq.com/symbol/itci
adr_tso
EBITDA EBITDA(百万ドル) -132.42960
終値(lastsale) 18.42
時価総額(marketcap) 1007744790.24
時価総額 時価総額(百万ドル) 996.25590
売上高 売上高(百万ドル) 0.03581
企業価値(EV) 企業価値(EV)(百万ドル) 592.49140
当期純利益 当期純利益(百万ドル) -127.03560
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intra-Cellular Therapies Inc revenues decreased from $210K to $0K. Net loss increased 63% to $72.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 91% to $59.3M (expense) General and administrative - Balancing v increase of 20% to $8.3M (expense).

 ITCIのテクニカル分析


 ITCIのニュース

   Looking Into Intra-Cellular Therapies''s Return On Capital Employed  2021/06/23 14:48:48 Benzinga
During Q1, Intra-Cellular Therapies (NASDAQ: ITCI ) brought in sales totaling $15.88 million. However, earnings decreased 13.23%, resulting in a loss of $53.22 million. In Q4, Intra-Cellular Therapies brought in $12.45 million in sales but lost $61.33 million in earnings. Why ROCE Is Significant Changes in earnings and sales indicate shifts in Intra-Cellular Therapies''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and Full story available on Benzinga.com
   CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology  2021/06/07 00:00:00 BioSpace
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), today announced the article, "Safety and tolerability of lumateperone: a pooled analysis of late-phase placebo-and active-controlled clinical trials (Kane et al. 2021), was recently published online in International Clinical Psychopharmacology
   Intra-Cellular Therapies (ITCI) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow  2021/06/04 21:29:18 Seeking Alpha
   Stress Medication Market Swot Analysis by key players Pfizer, Intra-Cellular Therapies, Alkermes  2021/05/30 00:00:00 iCrowdNewswire
The latest independent research document on Global Stress Medication examine investment in Market. It describes how companies deploying these technologies across various industry verticals aim to explore its potential to become []
   Does Earnings Surprise History Hold Any Clue for NASDAQ:ITCI, NASDAQ:CPRX, NASDAQ:OPEN, NASDAQ:EDAP  2021/05/14 19:03:00 Stock Market Daily
Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis The post Does Earnings Surprise History Hold Any Clue for NASDAQ:ITCI, NASDAQ:CPRX, NASDAQ:OPEN, NASDAQ:EDAP appeared first on .
   Looking Into Intra-Cellular Therapies''s Return On Capital Employed  2021/06/23 14:48:48 Benzinga
During Q1, Intra-Cellular Therapies (NASDAQ: ITCI ) brought in sales totaling $15.88 million. However, earnings decreased 13.23%, resulting in a loss of $53.22 million. In Q4, Intra-Cellular Therapies brought in $12.45 million in sales but lost $61.33 million in earnings. Why ROCE Is Significant Changes in earnings and sales indicate shifts in Intra-Cellular Therapies''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and Full story available on Benzinga.com
   CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology  2021/06/07 00:00:00 BioSpace
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), today announced the article, "Safety and tolerability of lumateperone: a pooled analysis of late-phase placebo-and active-controlled clinical trials (Kane et al. 2021), was recently published online in International Clinical Psychopharmacology
   Intra-Cellular Therapies (ITCI) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow  2021/06/04 21:29:18 Seeking Alpha
   Stress Medication Market Swot Analysis by key players Pfizer, Intra-Cellular Therapies, Alkermes  2021/05/30 00:00:00 iCrowdNewswire
The latest independent research document on Global Stress Medication examine investment in Market. It describes how companies deploying these technologies across various industry verticals aim to explore its potential to become []
   Does Earnings Surprise History Hold Any Clue for NASDAQ:ITCI, NASDAQ:CPRX, NASDAQ:OPEN, NASDAQ:EDAP  2021/05/14 19:03:00 Stock Market Daily
Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis The post Does Earnings Surprise History Hold Any Clue for NASDAQ:ITCI, NASDAQ:CPRX, NASDAQ:OPEN, NASDAQ:EDAP appeared first on .
   RBC Capital Stick to Their Buy Rating for Intra-Cellular Therapies By Investing.com  2021/04/12 01:46:54 Investing.com
RBC Capital Stick to Their Buy Rating for Intra-Cellular Therapies
   Leerink Partners Stick to Their Buy Rating for Intra-Cellular Therapies By Investing.com  2021/03/02 14:48:43 Investing.com
Leerink Partners Stick to Their Buy Rating for Intra-Cellular Therapies
   Intra-Cellular Therapies (NASDAQ:ITCI) Posts Earnings Results, Beats Estimates By $0.09 EPS  2021/02/27 17:22:55 Transcript Daily
Intra-Cellular Therapies (NASDAQ:ITCI) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.09, MarketWatch Earnings reports. Intra-Cellular Therapies had a negative net margin of 1,985.32% and a negative return on equity of 48.27%. Shares of ITCI stock traded down […]
   Canaccord Genuity Stick to Their Buy Rating for Intra-Cellular Therapies By Investing.com  2021/02/26 11:37:03 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Intra-Cellular Therapies
   Mark Neumann Sells 5,184 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock  2021/02/25 10:44:41 Watchlist News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Mark Neumann sold 5,184 shares of the company’s stock in a transaction dated Friday, February 19th. The shares were sold at an average price of $39.22, for a total transaction of $203,316.48. Following the completion of the transaction, the executive vice president now owns 50,523 shares in the company, valued […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イントラセルラ―・セラピ―ズ ITCI Intra-Cellular Therapies Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)